XML 25 R16.htm IDEA: XBRL DOCUMENT
v3.22.1

Stock Option | 9 Months Ended
--- | ---
Mar. 31, 2022
Stock Option |
Stock Option | NOTE 9 - Stock Option The Company follows ASC 718 (“Share-Based Payment”), which requires that all share-based payments to employees, including stock options, be recognized as compensation expense in the consolidated financial statements based on their fair values and over the requisite service period. For the three months ended March 31, 2022 and 2021, the Company recorded non-cash compensation expense of $35,000 ($0.00 per basic and diluted share) and $84,000 ($0.00 per basic and diluted share), respectively, relating to stock-based compensation. For the nine months ended March 31, 2022 and 2021, the Company recorded non-cash compensation expense of $1,379,000 ($0.04 per basic and diluted share) and $272,000 ($.01 per basic and diluted share). 2012 Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Employee Stock Option Plan (the 2012 Employee Plan). The 2012 Employee Plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 1,900,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options, which are intended to qualify as incentive stock options (ISOs) or non-incentive stock options, to valued employees. Any plan participant who is granted ISOs and possesses more than 10% of the voting rights of the Company’s outstanding common stock must be granted an option with a price of at least 110% of the fair market value on the date of grant. Under the 2012 Employee Plan, stock options may be granted to valued employees with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable, in whole or in part, at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2022, 523,080 stock options were outstanding, 164,776 stock options were exercisable and 1,138,920 stock options were available for grant under this plan. No options may be granted under this plan after December 2022. 338,000 Options were granted during the nine months ended March 31, 2022. There were no options granted during the three months ended March 31, 2022. There were no options granted during the three or nine months ended March 31, 2021. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2021 |
Risk-free interest rates | ​ | 1.64 | % | n/a | %
Expected lives | ​ | 6.18 Years | ​ | n/a | ​
Expected volatility | ​ | 43 | % | n/a | %
Expected dividend yields | ​ | 0 | % | n/a | %
​ The following table reflects activity under the 2012 Employee Plan for the nine months ended March 31: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​
​ | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average | ​
​ |  | Options |  | exercise price |  | Options |  | exercise price |
Outstanding, beginning of year | ​ | ​ | 214,080 | ​ | $ | 9.59 | ​ | ​ | 235,680 | ​ | $ | 9.42 | ​
Granted | ​ | ​ | 338,000 | ​ | $ | 23.17 | ​ | ​ | — | ​ | ​ | — | ​
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (8,000) | ​ | $ | 4.08 | ​
Exercised | ​ | ​ | (29,000) |  | $ | 5.45 | ​ |  | (3,600) |  | $ | 5.70 | ​
Outstanding, end of period | ​ | ​ | 523,080 | ​ | $ | 18.59 | ​ |  | 224,080 | ​ | $ | 9.67 | ​
Exercisable, end of period | ​ | ​ | 164,776 | ​ | $ | 15.01 | ​ |  | 89,200 | ​ | $ | 7.92 | ​
Weighted average fair value at grant date of options granted | ​ | $ | 12.16 | ​ |  | ​ | ​ | ​ | n/a | ​ |  | ​ | ​
Total intrinsic value of options exercised | ​ | $ | 502,000 | ​ | ​ | ​ | ​ | $ | 42,000 | ​ |  | ​ | ​
Total intrinsic value of options outstanding | ​ | $ | 1,903,000 | ​ | ​ | ​ | ​ | $ | 1,735,000 | ​ |  | ​ | ​
Total intrinsic value of options exercisable | ​ | $ | 1,085,000 | ​ | ​ | ​ | ​ | $ | 847,000 | ​ |  | ​ | ​
​ 1,000 and 29,000 stock options were exercised during the three and nine months ended March 31, 2022, respectively. The 1,000 options that were exercised during the three months ended March 31, 2022, were settled by exchanging 153 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. $155,000 cash was received from option exercises during the nine months ended March 31, 2022. The actual tax benefit realized for the tax deductions from option exercises during the three and nine months ended March 31, 2022 was $1,000 for both periods. 3,600 stock options were exercised during the three and nine months ended March 31, 2021, which were settled by exchanging 1,350 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. The actual tax benefit realized for the tax deductions from option exercises during the three and nine months ended March 31, 2021 was $3,000 for both periods. The following table summarizes information about stock options outstanding under the 2012 Employee Plan at March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | ​ | ​ |  | ​ |  | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | exercise price | ​ | exercisable | ​ | exercise price
$2.19 ‑ $24.75 | ​ | 523,080 | ​ | 8.67 | ​ | $ | 18.59 | ​ | 164,776 | ​ | $ | 15.01
​ | ​ | 523,080 | ​ | 8.67 | ​ | $ | 18.59 | ​ | 164,776 | ​ | $ | 15.01
​ As of March 31, 2022, there was $2,704,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Employee Plan. 0 and 338,000 options were granted during the three and nine months ended March 31, 2022, respectively. There were no options granted during each of the three and nine months ended March 31, 2021. 5,200 and 95,600 options vested during the three and nine months ended March 31, 2022, respectively. 5,200 and 30,800 options vested during the three and nine months ended March 31, 2021, respectively. The total grant date fair value of the options vesting during the three months ended March 31, 2022 and 2021 under this plan was $36,000 and $63,000, respectively. The total grant date fair value of the options vesting during the nine months ended March 31, 2022 and 2021 under this plan was $975,000 and $168,000, respectively. 2012 Non-Employee Stock Option Plan In December 2012, the stockholders approved the 2012 Non-Employee Stock Option Plan (the 2012 Non-Employee Plan). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company’s common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2012 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2022, 21,600 stock options were outstanding, 12,480 stock options were exercisable and no further stock options were available for grant under this plan. 9,600 Options were granted during the nine months ended March 31, 2022. There were no options granted during the three months ended March 31, 2022. There were no options granted during the three or six months ended March 31, 2021. No options may be granted under this plan after December 2022. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​
​ | 2022 |  | 2021 |
Risk-free interest rates | 1.68 | % | n/a | %
Expected lives | 6.18 Years | ​ | n/a | ​
Expected volatility | 43 | % | n/a | %
Expected dividend yields | 0 | % | n/a | %
​ The following table reflects activity under the 2012 Non-Employee Plan for the nine months ended March 31: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​
​ |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average |
​ | ​ | Options | ​ | exercise price | ​ | Options | ​ | exercise price | ​
Outstanding, beginning of year | ​ | ​ | 12,000 | ​ | $ | 6.55 | ​ | ​ | 24,000 | ​ | $ | 5.15 | ​
Granted | ​ | ​ | 9,600 | ​ | $ | 22.93 | ​ | ​ | — | ​ | ​ | — | ​
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​
Exercised | ​ | ​ | — | ​ | ​ | — | ​ |  | (2,400) |  | $ | 4.35 | ​
Outstanding, end of period | ​ | ​ | 21,600 | ​ | $ | 13.83 | ​ |  | 21,600 | ​ | $ | 5.23 | ​
Exercisable, end of period | ​ | ​ | 12,480 | ​ | $ | 8.48 | ​ |  | 14,640 | ​ | $ | 4.57 | ​
Weighted average fair value at grant date of options granted | ​ | $ | 12.58 | ​ | ​ | ​ | ​ | ​ | n/a | ​ |  |  | ​
Total intrinsic value of options exercised | ​ | ​ | n/a | ​ | ​ | ​ | ​ | $ | 31,000 | ​ |  |  | ​
Total intrinsic value of options outstanding | ​ | $ | 168,000 | ​ | ​ | ​ | ​ | $ | 263,000 | ​ |  |  | ​
Total intrinsic value of options exercisable | ​ | $ | 155,000 | ​ | ​ | ​ | ​ | $ | 188,000 | ​ |  |  | ​
​ No stock options were exercised during the three or nine months ended March 31, 2022 or 2021. No cash was received from option exercises during either of the three or nine months ended March 31, 2022 or 2021 and the actual tax benefit realized for the tax deductions from option exercises was $0. 2,400 stock options were exercised during the three and nine months ended March 31, 2021, which were settled by exchanging 913 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. The actual tax benefit realized for the tax deductions from option exercises was $6,000 for both periods. The following table summarizes information about stock options outstanding under the 2012 Non-Employee Plan at March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | Weighted | ​ | ​ | ​ | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding |  | contractual life | ​ | price |  | exercisable | ​ | price
$4.35 - $22.93 | ​ | 21,600 | ​ | 7.78 | ​ | $ | 13.83 | ​ | 12,480 | ​ | $ | 8.48
​ | ​ | 21,600 | ​ | 7.78 | ​ | $ | 13.83 | ​ | 12,480 | ​ | $ | 8.48
​ As of March 31, 2022, there was $76,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2012 Non-Employee Plan. 0 and 9,600 options were granted during the three and nine months ended March 31, 2022. No options were granted during the three or nine months ended March 31, 2021. 720 and 6,240 options vested during the three and nine months ended March 31, 2022. 720 and 5,520 options vested during the three and nine months ended March 31, 2021. The total grant date fair value of the options vesting during the three months ended March 31, 2022 and 2021 under this plan was $5,000, for each period. The total grant date fair value of the options vesting during the nine months ended March 31, 2022 and 2021 under this plan was $39,000 and $18,000, respectively. 2018 Non-Employee Stock Option Plan In December 2018, the stockholders approved the 2018 Non-Employee Stock Option Plan (the “2018 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2018 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2022, 89,000 stock options were outstanding, 45,040 stock options were exercisable and no further stock options were available for grant under this plan. 23,500 Options were granted during the nine months ended March 31, 2022. There were no options granted during the three months ended March 31, 2022. There were no options granted during the three or nine months ended March 31, 2021. No options may be granted under this plan after December 2028. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 |  | 2021 |
Risk-free interest rates | ​ | 1.68 | % | n/a | %
Expected lives | ​ | 6.18 Years | ​ | n/a | ​
Expected volatility | ​ | 43 | % | n/a | %
Expected dividend yields | ​ | 0 | % | n/a | %
​ The following table reflects activity under the 2018 Non-Employee Plan for the three months ended March 31: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​
​ |  | ​ | ​ |  | Weighted average |  | ​ | ​ |  | Weighted average |
​ | ​ | Options |  | exercise price | ​ | Options |  | exercise price | ​
Outstanding, beginning of year | ​ | ​ | 70,100 | ​ | $ | 11.93 | ​ | ​ | 96,800 | ​ | $ | 11.74 | ​
Granted | ​ | ​ | 23,500 |  | $ | 22.93 | ​ |  | — |  | ​ | — | ​
Forfeited/Lapsed | ​ | ​ | — |  | ​ | — | ​ |  | — |  | ​ | — | ​
Exercised | ​ | ​ | (4,600) |  | $ | 10.43 | ​ |  | (3,200) |  | $ | 8.10 | ​
Outstanding, end of period | ​ | ​ | 89,000 | ​ | $ | 14.91 | ​ |  | 93,600 | ​ | $ | 11.87 | ​
Exercisable, end of period | ​ | ​ | 45,040 | ​ | $ | 12.98 | ​ |  | 40,960 | ​ | $ | 11.54 | ​
Weighted average fair value at grant date of options granted | ​ | $ | 12.58 | ​ | ​ | ​ | ​ | ​ | n/a | ​ | ​ | ​ | ​
Total intrinsic value of options exercised | ​ | $ | 58,000 | ​ | ​ | ​ | ​ | $ | 30,000 | ​ | ​ | ​ | ​
Total intrinsic value of options outstanding | ​ | $ | 556,000 | ​ | ​ | ​ | ​ | $ | 519,000 | ​ | ​ | ​ | ​
Total intrinsic value of options exercisable | ​ | $ | 351,000 | ​ | ​ | ​ | ​ | $ | 241,000 | ​ | ​ | ​ | ​
​ 1,600 and 4,600 options were exercised during the three months and nine months ended March 31, 2022. The 1,600 options that were exercised during the three months ended March 31, 2022, were settled by exchanging 663 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. The 4,600 options that were exercised during the nine months ended March 31, 2022, were settled by exchanging 2,075 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. No cash was received from option exercises during either of the three or nine months ended March 31, 2022 and the actual tax benefit realized for the tax deductions from option exercises was $4,000 and $12,000, respectively. 3,200 stock options were exercised during the three and nine months ended March 31, 2021, were settled by exchanging 1,217 shares of the Company’s common stock which were retired and returned to unissued status upon receipt. No cash was received from option exercises during either of the three and nine months ended March 31, 2021 and the actual tax benefit realized for the tax deductions from option exercises was $6,000 for both periods. The following table summarizes information about stock options outstanding under the 2018 Non-Employee Plan at March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ |  | ​ |  | Weighted average |  | Weighted |  | ​ |  | Weighted
​ | ​ | Number | ​ | remaining | ​ | average exercise | ​ | Number | ​ | average exercise
Range of exercise prices | ​ | outstanding | ​ | contractual life | ​ | price | ​ | exercisable | ​ | price
$8.10 - $22.93 | ​ | 89,000 |  | 8.00 | ​ | $ | 14.91 |  | 45,040 | ​ | $ | 12.98
​ | ​ | 89,000 |  | 8.00 | ​ | $ | 14.91 |  | 45,040 | ​ | $ | 12.98
​ As of March 31, 2022, there was $302,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2018 Non-Employee Plan. 0 and 23,500 options were granted during the three and nine months ended March 31, 2022. No options were granted during the three or nine months ended March 31, 2021. 5,380 and 19,680 options vested during the three and nine months ended March 31, 2022. 6,880 and 19,680 options vested during the three and nine months ended March 31, 2021. The total grant date fair value of the options vesting during the three months ended March 31, 2022 and 2021 under this plan was $35,000 and $45,000, respectively. The total grant date fair value of the options vesting during the nine months ended March 31, 2022 and 2021 under this plan was $160,000 and $133,000, respectively. 2020 Non-Employee Stock Option Plan In May 2020, the stockholders approved the 2020 Non-Employee Stock Option Plan (the “2020 Non-Employee Plan”). This plan authorizes the granting of awards, the exercise of which would allow up to an aggregate of 100,000 shares of the Company's common stock to be acquired by the holders of such awards. Under this plan, the Company may grant stock options to non-employee directors and consultants to the Company and its subsidiaries. Under the 2020 Non-Employee Plan, stock options may be granted with a term of up to 10 years at an exercise price equal to or greater than the fair market value on the date of grant and are exercisable in whole or in part at 20% per year beginning on the date of grant. An option granted under this plan shall vest in full upon a “change in control” as defined in the plan. At March 31, 2022, 26,900 stock options were outstanding, 7,380 stock options were exercisable and 73,100 stock options were available for grant under this plan. 16,900 and 10,000 Options were granted during the nine months ended March 31, 2022 and 2021, respectively. There were no options granted during the three months ended March 31, 2022 and 2021, respectively. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2021 |
Risk-free interest rates |  | 1.68 | % | 0.62 | %
Expected lives |  | 6.18 Years | ​ | 10 | ​
Expected volatility |  | 43 | % | 45 | %
Expected dividend yields |  | 0 | % | 0 | %
​ The following table reflects activity under the 2020 Non-Employee Plan for the three months ended March 31: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2022 | ​ | 2021 | ​
​ | ​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | Weighted average | ​
​ |  | Options |  | exercise price | ​ | Options |  | exercise price | ​
Outstanding, beginning of year |  | ​ | 10,000 |  | $ | 11.40 | ​ | ​ | — |  | ​ | — | ​
Granted |  | ​ | 16,900 | ​ | $ | 22.93 | ​ | ​ | 10,000 | ​ | $ | 11.40 | ​
Forfeited/Lapsed | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​
Exercised |  | ​ | — | ​ |  | — | ​ | ​ | — | ​ |  | — | ​
Outstanding, end of period |  | ​ | 26,900 | ​ | $ | 18.64 | ​ | ​ | 10,000 | ​ | $ | 11.40 | ​
Exercisable, end of period |  | ​ | 7,380 | ​ | $ | 16.68 | ​ | ​ | 2,000 | ​ | $ | 11.40 | ​
Weighted average fair value at grant date of options granted | ​ | $ | 12.58 | ​ |  |  | ​ | $ | 6.10 | ​ |  | ​ | ​
Total intrinsic value of options exercised | ​ |  | n/a | ​ |  |  | ​ |  | n/a | ​ |  | ​ | ​
Total intrinsic value of options outstanding | ​ | $ | 91,000 | ​ |  |  | ​ | $ | 60,000 | ​ |  | ​ | ​
Total intrinsic value of options exercisable | ​ | $ | 36,000 | ​ |  |  | ​ | $ | 12,000 | ​ |  | ​ | ​
​ No stock options were exercised during the three or nine months ended March 31, 2022 or 2021. No cash was received from option exercises during either of the three or nine months ended March 31, 2022 or 2021 and the actual tax benefit realized for the tax deductions from option exercises was $0 for both periods. The following table summarizes information about stock options outstanding under the 2020 Non-Employee Plan at March 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options outstanding | ​ | Options exercisable
​ | ​ | ​ | ​ | Weighted average | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number | ​ | remaining | ​ | Weighted average | ​ | Number | ​ | Weighted average
Range of exercise prices |  | outstanding |  | contractual life |  | exercise price |  | exercisable |  | exercise price
$11.40 - $22.93 |  | 26,900 |  | 9.14 | ​ | $ | 18.64 |  | 7,380 | ​ | $ | 16.68
​ |  | 26,900 |  | 9.14 | ​ | $ | 18.64 |  | 7,380 | ​ | $ | 16.68
​ As of March 31, 2022, there was $147,000 of unearned stock-based compensation cost related to share-based compensation arrangements granted under the 2020 Non-Employee Plan. 16,900 and 10,000 options were granted during the nine months ended March 31, 2022 and 2021, respectively. There were 0 options granted during the three months ended March 31, 2022 and 2021, respectively. 0 and 5,380 options vested during the three and nine months ended March 31, 2022, respectively. 0 and 2,000 options vested during the three and nine months ended March 31, 2021, respectively. The total grant date fair value of the options vesting during the three and nine months ended March 31, 2022 under this plan was $0 and $55,000, respectively. The total grant date fair value of the options vesting during the three and nine months ended March 31, 2021 under this plan was $0 and $12,000, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration